Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
Rhea-AI Summary
Mesoblast (Nasdaq:MESO) reported real-world pediatric outcomes for Ryoncil (remestemcel-L-rknd) since commercial launch in March 2025. Of the first 25 children treated post-launch, 21 (84%) completed the FDA-label 28-day regimen and were alive; four patients who did not complete treatment died within 28 days. Mesoblast has onboarded 45 transplant centers toward a 64-center target covering 94% of U.S. transplants, and reports payer coverage for over 260 million U.S. lives. A CMS HCPCS J-Code issued Oct 1, 2025 increased CMS usage in the last quarter. A pivotal adult trial with BMT-CTN is expected to begin site enrollment this quarter to seek FDA label expansion.
Positive
- 84% survival (21 of 25) completed 28-day pediatric regimen
- 45 transplant centers onboarded toward 64-center target
- Payer coverage for 260 million U.S. lives including CMS Medicaid
- CMS issued specific HCPCS J-Code (Oct 1, 2025) improving reimbursement
Negative
- Small early cohort: real-world results based on only 25 patients
- Four treated children died within 28 days and did not complete therapy
- Recent uptake skewed toward CMS coverage versus commercial payers
News Market Reaction – MESO
In the Jan 27 session, MESO gained 2.62%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 18 | FDA feedback CLBP | Positive | -3.5% | FDA Type B feedback that Phase 3 pain data support rexlemestrocel-L efficacy. |
| Jan 08 | Sales and financing | Positive | +3.2% | Ryoncil quarterly sales rose to US$35.1M with a 60% sequential increase. |
| Jan 01 | Board changes | Neutral | +0.7% | Board leadership reshaped to support shift toward revenue-generating commercialization. |
| Dec 29 | Credit facility | Positive | -2.0% | New five-year, interest-only facility used to retire senior debt and refinance. |
| Dec 11 | ASH meta-analysis | Positive | -1.8% | Meta-analysis showed remestemcel-L superior to ruxolitinib in SR-aGvHD outcomes. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows multiple instances where positive clinical or financing updates were followed by negative price reactions, alongside at least one strong positive reaction to commercial sales growth.
Over the past few months Mesoblast has transitioned from pure development to commercialization. In December 2025, it used a new US$75M credit facility to retire senior debt, then reported a 60% quarterly Ryoncil sales jump to US$35.1M on Jan 8, 2026. Subsequent FDA feedback on rexlemestrocel-L in back pain and an ASH meta‑analysis favoring remestemcel‑L over ruxolitinib were clinically positive but saw negative price reactions. Today’s real‑world Ryoncil survival data fits the ongoing commercialization narrative.
Key Terms
steroid-refractory acute graft-versus-host disease medical
sr-agvhd medical
mesenchymal stromal cell medical
u.s. food & drug administration regulatory
hcpcs regulatory
j-code regulatory
pivotal trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil® (remestemcel-L-rknd) since commercially available in March 2025 for the approved label in children 2 months and older with steroid-refractory acute graft-versus-host disease (SR-aGvHD). Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food & Drug Administration (FDA) for any indication.1
Of the first 25 patients treated with Ryoncil® in a ‘real-world’ clinical setting post launch, 21 were alive (
To ensure that no patient is left behind in receiving this potentially life-saving therapy, Mesoblast has established a patient access hub termed MyMesoblast™, where Ryoncil® is available for ordering. Additional information is available on ryoncil.com, where valuable resources for healthcare providers, patients and caregivers can be found.
To date 45 transplant centers have been onboarded, with a target of 64 centers which account for
These commercial activities will continue to serve the company well as it seeks to expand the FDA label for Ryoncil® to adults with severe SR-aGvHD, a market size approximately three times that of the pediatric SR-aGvHD population. A pivotal trial of Ryoncil® in adults with severe SR-aGvHD will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN) and is expected to commence site enrollment this quarter.
“We are delighted to see the excellent early survival rates in the real-world experience with Ryoncil® in children with this devastating disease,” said Mesoblast Chief Executive Dr. Silviu Itescu. “Our strong early results and the streamlined process that is in place to provide access to the product underscores the importance of early physician referral and treatment initiation in order to give Ryoncil® the best chance to save as many precious lives as possible."
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
References / Footnotes
- Please see the full Prescribing Information at www.ryoncil.com
- Coding and coverage decisions are made by payers, and coverage cannot be guaranteed
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGvHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
Corporate Communications / Investors
Paul Hughes
T: +61 3 9639 6036
Media – Global
Allison Worldwide
Emma Neal
T: +1 603 545 4843
E: emma.neal@allisonworldwide.com
Media – Australia
BlueDot Media
Steve Dabkowski
T: +61 419 880 486
E: steve@bluedot.net.au
